These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25773656)

  • 1. Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience.
    Epis O; Casu C; Belloli L; Schito E; Filippini D; Muscarà M; Bruschi E
    Rheumatol Int; 2015 Sep; 35(9):1569-70. PubMed ID: 25773656
    [No Abstract]   [Full Text] [Related]  

  • 2. Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis.
    Saito S; Kaneko Y; Izumi K; Takeuchi T
    J Rheumatol; 2017 May; 44(5):553-557. PubMed ID: 28298563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years.
    Suzuki T; Hirota T; Ogishima H; Umeda N; Kondo Y; Yokosawa M; Miki H; Tsuboi H; Matsumoto I; Sumida T
    Int J Rheum Dis; 2015 Jan; 18(1):108-10. PubMed ID: 25294091
    [No Abstract]   [Full Text] [Related]  

  • 4. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study.
    Yabe Y; Kojima T; Kaneko A; Asai N; Kobayakawa T; Ishiguro N
    Mod Rheumatol; 2013 Mar; 23(2):245-53. PubMed ID: 22526833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.
    Balsa A; Tovar Beltrán JV; Cáliz Cáliz R; Mateo Bernardo I; García-Vicuña R; Rodríguez-Gómez M; Belmonte Serrano MA; Marras C; Loza Cortina E; Pérez-Pampin E; Vila V
    Rheumatol Int; 2015 Sep; 35(9):1525-34. PubMed ID: 25773655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results.
    Benucci M; Manfredi M; Saviola G; Sarzi-Puttini P; Atzeni F
    Clin Exp Rheumatol; 2013; 31(2):322-3. PubMed ID: 23380047
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
    Gossec L; Steinberg G; Rouanet S; Combe B
    Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
    Kawashiri SY; Nishino A; Suzuki T; Nakashima Y; Horai Y; Ueki Y; Aramaki T; Fujikawa K; Nakashima M; Okada A; Migita K; Mizokami A; Matsuoka N; Mine M; Sakito S; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Eguchi K; Kawakami A
    Clin Exp Rheumatol; 2016; 34(5):808-812. PubMed ID: 27384149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study.
    Terenzi R; Santoboni G; Bartoloni E; Alunno A; Luccioli F; Gerli R
    Clin Exp Rheumatol; 2015; 33(3):445. PubMed ID: 25937244
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis.
    Aguilar-Lozano L; Castillo-Ortiz JD; Vargas-Serafin C; Morales-Torres J; Sanchez-Ortiz A; Sandoval-Castro C; Padilla-Ibarra J; Hernandez-Cuevas C; Ramos-Remus C
    J Rheumatol; 2013 Jul; 40(7):1069-73. PubMed ID: 23729804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice.
    Kojima T; Kaneko A; Hirano Y; Ishikawa H; Miyake H; Takagi H; Yabe Y; Kato T; Terabe K; Fukaya N; Tsuchiya H; Shioura T; Funahashi K; Hayashi M; Kato D; Matsubara H; Ishiguro N
    Mod Rheumatol; 2012 Jun; 22(3):370-5. PubMed ID: 21931942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline low modified health assessment questionnaire (MHAQ) predicts the state of remission estimated by clinical disease activity index and MHAQ at 1 year in tocilizumab-treated rheumatoid arthritis patients.
    Kawashiri S; Ueki Y; Migita K; Nakamura H; Aoyagi K; Kawakami A
    Clin Exp Rheumatol; 2014; 32(3):445. PubMed ID: 24850342
    [No Abstract]   [Full Text] [Related]  

  • 16. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.
    Nishina N; Kikuchi J; Hashizume M; Yoshimoto K; Kameda H; Takeuchi T
    Ann Rheum Dis; 2014 May; 73(5):945-7. PubMed ID: 24336338
    [No Abstract]   [Full Text] [Related]  

  • 18. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
    Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.